NeoAdjuvant Dynamic marker - Adjusted Personalized Therapy comparing sacituzumab govitecan+pembrolizumab vs. SoC chemotherapy in clinical stage II-III, triple-negative early breast cancer (ADAPT-TN-IV)

Overview

Sponsor-declared trial summary

Key facts

Sponsor

WSG Westdeutsche Studiengruppe GmbH

Participant type

Patients

Age range

18-64 years, 65+ years

Gender

Male and Female

Therapeutic area

Diseases [C] - Neoplasms [C04]

Decision date (initial)

2026-05-15

Transition trial

No

Low-intervention

No

Rare-disease indication

No

Vulnerable population

Yes

Funding sources

Gilead Sciences GmbH

Trial design

CTIS Part I — objectives, methods, condition coding

Main objective

Scope: Efficacy, Safety, Therapy

For cohort I, the primary objective of the study is to analyse 3-year EFS
For cohort II, the primary objectives are
a. to demonstrate superiority of neoadjuvant treatment with SG+PEM vs. SoC with regards to EFS after 3 years, and
b. to demonstrate superiority of neoadjuvant treatment with SG+PEM vs. SoC with regards to pCR rates

Secondary objectives 4

1. To assess clinical response after 12 weeks of neoadjuvant chemotherapy treatment
2. To assess 3-year distant disease-free survival (dDFS), relapse-free survival (RFS), locoregional relapse-free survival (LRFS), and OS
3. To assess health-related quality of life (HRQoL via questionnaires EORTC-QLQ-C30, version 3.0, EORTC QLQ-BR42, for female patients and adapted EORTC QLQ-BR42 for male patients, version 1.0, CANKADO active)
4. For cohort II only: To assess toxicity

Conditions and MedDRA coding

triple-negative early breast cancer

Study design 4 periods

Eligibility criteria

Principal inclusion / exclusion criteria as submitted by sponsor

Inclusion criteria 21

1. TNBC: ER = 0%, PR = 0%, and HER2- (i.e., immunohistochemistry [IHC] with DAKO score ≤ 1 or fluorescence in situ hybridization [FISH]- negative)
2. or TNBC-like: ER ≤ 10% positive cells in IHC, PR < 10% positive cells in IHC, and HER2- (i.e., IHC with DAKO score ≤ 1 or FISH negative) (if treatment is planned as TNBC by investigator, second pathology re- assessment strongly recommended,
3. All patients, independent from gender
4. ≥18 years at diagnosis
5. Histologically confirmed unilateral, primary invasive carcinoma of the breast Note: bilateral, multicentric, or multifocal carcinoma may be included, if there is a clear target (primary) lesion, that is subject to treatment decisions and solely evaluated and documented for study purposes. Histological confirmation of all lesions as TNBC is mandatory.
6. Clinical stage II – III at baseline
7. No clinical evidence for distant metastasis (M0)
8. Cognitive and language skills to complete quality of life (QoL) questionnaires
9. Completed 9-12 weeks of NACT, considered as CARBO/PAC + PEM with the last dose of NACT given less than 2 weeks ago. Patients may also be considered if their NACT treatment was switched to nab-PAC due to intolerance to PAC. Patients with progressive disease during CARBO/PAC + PEM treatment are allowed to participate in cohort II after consultation with sponsor, provided that at least 6-9 weeks of NACT with CARBO/PAC + PEM have been administered o Patients experiencing toxicities due to PEM, in case of contraindications or other medical reasons against PEM administration (with or without permanent discontinuation of PEM) can nevertheless be included, even if PEM will not be administered anymore. The number of patients starting the study without PEM is limited to 10%.
10. Tumour block available for central pathology review
11. Performance Status ECOG ≤ 1 or Karnofsky Index ≥ 80%
12. Written informed consent prior to beginning specific protocol procedures, including expected cooperation of the patients for the treatment and follow- up, must be obtained and documented according to the local regulatory requirements
13. The patient must be capable of giving informed consent and be willing and able to comply with the requirements and restrictions in this protocol and accessible for treatment and follow-up
14. Laboratory requirements (female and male patients, ≤ 14 days old): for details see protocol
15. Clinical assessments: • Normal Electrocardiogram (ECG) (within 42 days prior to induction treatment)
16. Negative pregnancy test (urine or serum) within ≤ 14 days prior to registration in premenopausal patients and immediate implementation of adequate contraceptive measures. Note: Pregnancy testing is to be repeated according to Schedule of Activities.
17. The following age-specific requirements apply: • Women aged <50 years will be considered post-menopausal if they have been amenorrhoeic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels in the post-menopausal range for the site. • Women aged ≥ 50 years will be considered post-menopausal if they have been amenorrhoeic for 12 months or more following cessation of all exogenous hormonal treatments.
18. Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the contraception methods outlined for women of child-bearing potential and need to discontinue HRT to allow confirmation of post-menopausal status prior to randomization/study enrolment. For most forms of HRT, at least 2-4 weeks will elapse between the cessation of therapy and the blood draw; this interval depends on the type and dosage of HRT. Following confirmation of their post-menopausal status, they can participate without use of a contraceptive method.
19. Female patients of childbearing potential who are sexually active with a non-sterilized male partner must use at least one highly effective method of contraception, presented in Table 1 (see Section 4.4.2), from the time of enrolment and must agree to continue using such precautions for 7 months after the last dose of IMP. Not all methods of contraception are highly effective. Female patients must refrain from breastfeeding while on study and for 7 months after the last dose of IMP. Complete heterosexual abstinence for the duration of the study and drug washout period is an acceptable contraceptive method if it is line with the patient’s usual lifestyle (consideration must be made to the duration of the clinical trial); however, periodic, or occasional abstinence, the rhythm method, and the withdrawal method are not acceptable.
20. Female patients must not donate, or retrieve for their own use, ova from the time of randomization and throughout the study treatment period, and for at least 7 months after the final study drug administration. They should refrain from breastfeeding throughout this time. Preservation of ova may be considered prior to enrolment in this study.
21. A male participant must agree to use a contraception as detailed in Appendix C of this protocol during the treatment period and for at least 7 months after the last dose of study treatment and refrain from donating sperm during this period.

Exclusion criteria 18

1. Known hypersensitivity to the compounds or incorporated substances of the IMPs
2. Prior malignancy with a disease-free survival of < 5 years, except curatively treated basalioma of the skin or pTis of the cervix uteri
3. Any history of invasive breast cancer
4. Previous or concurrent treatment with cytotoxic agents for any non- oncological reason unless clarified with sponsor
5. Concurrent treatment with other experimental drugs
6. Participation in another interventional clinical trial with or without any investigational, not marketed drug within 30 days or 5 half-lives of the respective drug, whichever is longer, prior to study entry. In case of other interventional trial contact Sponsor.
7. Concurrent pregnancy: patients of childbearing potential or potentially childbearing partners of male patients must implement a highly effective (less than 1% failure rate) non-hormonal contraceptive measures during the study treatment
8. Breast feeding woman
9. Reasons indicating risk of poor compliance
10. Patients not able to consent
11. Known polyneuropathy ≥ grade 2
12. Severe and relevant co-morbidity that would interact with the application of cytotoxic agents or the participation in the study including recovery from major surgery, autoimmune disease, known psychiatric/substance abuse disorders, acute cystitis, ischuria, and chronic kidney disease
13. Uncontrolled infection requiring i.v. antibiotics, antivirals, or antifungals
14. History of pneumonitis haemolytic anaemia, myocarditis, sclerosing cholangitis and exocrine pancreatic insufficiency, medical history of allogenic stem cell transplants, or solid organ transplant
15. Active primary immunodeficiency, known human immunodeficiency virus (HIV) infection. Patients should be tested for HIV prior to randomization if required by local regulations or ethics committee. Patients who test positive for HIV-antibody are excluded.
16. Active hepatitis B virus (HBV) or hepatitis C virus (HCV). In patients with a history of HBV or HCV, patients with the following detectable viral loads will be excluded. • Patients who test positive for hepatitis B surface antigen (HBsAg). Patients who test positive for hepatitis B core antibody (anti-HBc) will require HBV DNA by quantitative polymerase chain reaction (PCR) for confirmation of active disease. • Patients who test positive for HCV antibody will require HCV RNA by quantitative PCR for confirmation of active disease. Patients with a known history of HCV or a positive HCV antibody test will not require an HCV antibody test at enrolment and will only require HCV RNA by quantitative PCR for confirmation of active disease.
17. Patients who received live vaccines within 30 days prior to randomization.
18. Patients who are submitted to an institution by virtue of an order of a court or a governmental authority must be excluded from participation.

Endpoints

Primary and secondary outcome measures (English text)

Primary endpoints 2

1. Primary endpoint in cohort I: • EFS after 36 months defined as time from registration to any invasive breast cancer event, death, or secondary malignancy (same definition as iDFS) according to STEEP 2.0 criteria
2. Primary endpoints in cohort II: • EFS after 36 months defined as time from registration to any invasive breast cancer event, death, or secondary malignancy or local progress precluding surgery in neoadjuvant treated patients • pCR defined as no invasive disease in breast and lymph nodes (ypT0/is, ypN0) in patients of both arms

Secondary endpoints 7

1. Clinical response measured by palpation, ultrasound, mammography, or MRI
2. OS defined as time from first diagnosis to death
3. 3-year dDFS
4. 3-year RFS each as defined in STEEP 2.0
5. 3-year LRFS
6. Change of HRQoL between baseline, after completion of SoC neoadjuvant treatment, and on following defined timepoints: for details see protocol
7. For cohort II only: Comparison of toxicity of regimen by evaluation of treatment-emergent adverse event (TEAE), adverse drug reactions (ADR), serious ADR (SADR), and serious adverse events (SAE)-rates

Investigational products

Investigational medicinal products (IMPs), comparators, placebo, auxiliary

Test 3

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

WSG Westdeutsche Studiengruppe GmbH

Sponsor organisation

WSG Westdeutsche Studiengruppe GmbH

Address

Fliethstrasse 112-114, Stadtmitte Stadtmitte

City

Moenchengladbach

Postcode

41061

Country

Germany

Scientific contact point

Organisation

WSG Westdeutsche Studiengruppe GmbH

Contact name

Medical Board

Public contact point

Organisation

WSG Westdeutsche Studiengruppe GmbH

Contact name

Project Management

Third parties 7

Locations

1 EU/EEA country · 26 investigational sites

By country

Investigational sites

Results and documents

Annex IV summary of results, Annex V layperson summary, and all documents registered in CTIS for this trial

Documents 24 files

Public protocol annexes, IB summaries, regulatory submissions and post-authorisation documents registered in CTIS.

Application history

1 submissions — initial application plus substantial / non-substantial modifications